Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of proteasome inhibitor in preparation of medicines for preventing and treating cardiovascular diseases

A proteasome inhibitor and proteasome technology, applied in cardiovascular system diseases, metabolic diseases, drug combinations, etc., can solve problems such as limiting clinical application

Inactive Publication Date: 2018-10-26
GUANGZHOU MEDICAL UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are currently no proteasome inhibitors for cardiovascular diseases such as cardiac hypertrophy, heart failure and diabetic cardiomyopathy
In addition, the adverse reactions of the above drugs (such as thrombocytopenia, peripheral neuropathy, neutropenia, etc.) limit the clinical application of these drugs to a certain extent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] In order to better understand the essence of the present invention, mice will be used as experimental subjects to illustrate its new application in the field of pharmacy.

[0022] 8-10 weeks old male C57 / B6 mice were selected to establish the type 1 diabetes model. C57 / B6 mice were injected intraperitoneally with small doses of streptozotocin STZ (45 mg / kg / day) for six consecutive days, and the dissolved STZ was placed on ice in the dark (the entire injection process should also be carried out quickly in the dark). The normal group was given the same amount of citrate buffer. On the third day after the STZ injection, fast for 6 hours, use a three-edged needle to puncture the femoral vein of the mouse's hind leg to collect blood. When the blood drips out more than 1 μl, drop it on the special test paper of Wenhao blood glucose meter to measure the blood sugar level. Fasting blood sugar was measured for three consecutive days. A blood glucose value higher than 16.7mmol / ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of a proteasome inhibitor in preparation of medicines for preventing and treating cardiovascular diseases, particularly relates to application of luteolin serving asa proteasome inhibitor in prevention and treatment of diabetic cardiomyopathy. The proteasome inhibitor is used for solving the problems that no traditional medicine is used for effectively preventing and treating diabetic cardiomyopathy and other cardiovascular diseases and existing clinical medicines have adverse responses in treatment, and provides a new thought and specific application for preventing and treating cardiomyopathy, cardiac failure and other cardiovascular diseases.

Description

technical field [0001] The invention relates to the use of proteasome inhibitors in the preparation of drugs for preventing and treating cardiovascular diseases Background technique [0002] Cardiac hypertrophy is a compensatory response of myocardial tissue to adapt to cardiac hemodynamic overload. At the cellular level, cardiac hypertrophy is mainly manifested as an increase in cell volume and weight; at the organ level, it is manifested as an increase in ventricular weight and thickening of the ventricular wall. Pathological myocardial hypertrophy is one of the independent risk factors leading to the increasing morbidity and mortality of various cardiovascular diseases (heart failure, atherosclerosis, myocardial infarction and hypertension, etc.). Under the stimulation of hypertrophic factors, the volume of cardiomyocytes increases and the weight of myocardial cells increases, accompanied by pathological changes such as apoptosis and necrosis of cardiomyocytes, prolifera...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/352A61P9/00A61P9/04A61P3/10
CPCA61K31/352A61K45/00A61P3/10A61P9/00A61P9/04
Inventor 刘英华薛勤穆巴拉克·热合甫田嘉慧吴茜
Owner GUANGZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com